A 68-year-old woman with advanced lung cancer develops a large left-sided malignant pleural effusion causing dyspnea and orthopnea. After therapeutic thoracentesis and imaging confirmation of malignancy, she is deemed a candidate for pleurodesis. What is the drug of choice for intrapleural instillation in this patient?

Explanation

## Malignant Pleural Effusion: Pleurodesis Agent Selection **Key Point:** Talc is the drug of choice (most effective sclerosing agent) for pleurodesis in malignant pleural effusions, with the highest success rates among all available agents and strong support from international guidelines (BTS, ACCP, ASCO). ### Why Talc is the Drug of Choice Talc (magnesium silicate) induces an intense inflammatory and fibrotic reaction on the pleural surfaces, leading to symphysis and obliteration of the pleural space. It is the most extensively studied and consistently most effective agent for pleurodesis. ### Efficacy Comparison | Agent | Success Rate | Guideline Status | Notes | | --- | --- | --- | --- | | **Talc** | 70–90% | **First-line / Drug of Choice** | Highest efficacy; BTS/ACCP preferred | | **Bleomycin** | 60–80% | Second-line alternative | More expensive; inferior to talc in meta-analyses | | **Doxycycline** | 40–70% | Third-line | Inferior efficacy | | **Iodopovidone** | 50–80% | Not standard | Potential iodine toxicity | **High-Yield:** The TIME2 trial and multiple meta-analyses (including Cochrane reviews) consistently demonstrate talc as the **most effective** sclerosing agent for malignant pleural effusions. Talc can be administered as a slurry via chest tube or as poudrage via thoracoscopy (VATS), with poudrage showing the highest success rates (~90%). ### Talc Administration - **Talc slurry:** 4–5 g talc in 50 mL normal saline instilled via chest tube - **Talc poudrage:** Insufflated during thoracoscopy — preferred method when available - Both methods are superior to bleomycin in head-to-head comparisons ### Why Not the Other Options? - **Bleomycin (Option B):** While historically used and still an acceptable alternative, bleomycin is inferior to talc in efficacy per meta-analyses and is more expensive. It is not the drug of choice per current BTS (2010) and ACCP guidelines. - **Doxycycline (Option C):** Inferior efficacy (40–70%); reserved for patients ineligible for talc or bleomycin. - **Iodopovidone (Option D):** Not a standard agent; risk of iodine absorption; not recommended in major guidelines. **Clinical Pearl:** Per the British Thoracic Society (BTS) Guidelines on Pleural Disease and multiple systematic reviews, **talc is the preferred sclerosing agent** for malignant pleural effusions due to its superior efficacy, low cost, and well-established safety profile. Concerns about talc-induced ARDS are mitigated by using graded (large-particle) talc preparations. *Reference: BTS Pleural Disease Guideline 2010; Antunes G et al., Thorax 2003; Dresler CM et al., Chest 2005 (TIME trial); Light RW, Harrison's Principles of Internal Medicine.*